Skip to main content
. 2018 Nov 14;22:298. doi: 10.1186/s13054-018-2251-2

Table 1.

Main characteristics of included studies

Study Type of surgery Patients (GDFT), n Patients (control), n Risk Age, years GDFTdyn goals Other goals Monitoring devices Interventions
Benes J
2010 [13]		 Major abdominal 60 60 High > 18 SVV < 10% CI 2.5–4 L/min/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Broch O
2016 [14]		 Major abdominal 39 40 High > 18 PPV < 10%a CI > 2.5 L/min/m2 Nexfinb Fluid inotropes vasopressors
Buettner M
2008 [15]		 Major abdominal 40 40 High > 18 SPV < 10% – PiCCOplus Fluid
vasopressor
Cesur S
2018 [16]		 Abdominal 35 35 Moderate > 18 PVI < 13% – Masimo Radical 7b Fluid vasopressors
Colantonio L
2015 [17]		 Major abdominal 38 42 High > 18 SVV < 15% SVI > 35 mL/min/m2 CI > 2.5 L/min/m2 FloTrac/Vigileo Fluid inotropes
Correa-Gallego C
2015 [18]		 Major abdominal 69 66 High NR SVV < 15% CO > 4 L/min CI > 2 L/min/m2 FloTrac Fluid
Demirel İ
2018 [19]		 Abdominal 30 30 Moderate > 18 PVI < 14% – Masimo Co.b Fluid vasopressors
Elgendy MA
2017 [20]		 High risk 43 43 High NR SVV < 12% CI > 2.5 L/min/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Fellahi JL
2015 [21]		 Cardiac 48 44 High > 18 SVV ≤11% CI > 2.4 L/min/m2 Endotracheal cardiac output monitor Fluid inotropes
Forget P
2010 [22]		 Abdominal 41 41 Moderate > 18 PVI < 13% – Masimo Co.b Fluid vasopressors
Funk DJ
2015 [23]		 Major vascular 20 20 High > 18 SVV < 13% CI > 2.2 L/min/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Goepfert MS
2013 [24]		 Cardiac 50 50 High > 18 SVV < 10% CI > 2 L/min/m2 PiCCOplus Fluid inotropes vasopressors
Hand WR
2016 [25]		 Head and neck 47 47 Moderate NR SVV < 13% CI > 3 L/min/m2 SVR > 800 dynes/s/cm5/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Harten J
2008 [26]		 Emergency abdominal 14 15 High > 50 PPV < 10% – Lidco plus Fluid
Kapoor PM
2008 [27]		 Cardiac 13 14 High NR SVV < 10%a CI 2.5–4.2 L/min/m2 SVI 30-65 mL/beat/m2 SVRI: 1500–2500 dynes/s/cm5/m2 DO2 450–600 mL/min/m2 ScVO2 > 70% FloTrac/Vigileo Fluid inotropes vasoactives
Kapoor PM
2016 [28]		 Cardiac 60 60 High NR SVV < 10%a CI 2.5–4.2 L/min/m2 SVI 30–65 mL/beat/m2 SVRI 1500–2500 dynes/s/cm5/m2 DO2 450–600 mL/min/m2 ScVO2 > 70% Hct > 30% ScVO2 > 70% FloTrac/Vigileo Fluid inotropes vasodilators
Kim HJ
2018 [29]		 Head and neck 31 31 Moderate 20–80 SVV < 12% CI > 2.5 L/min/m2 FloTrac/Vigileo Fluid inotropes vasodilators
Kumar L
2016 [30]		 Major abdominal 30 30 High > 18 SVV < 10% CI ≥2.5 L/min/m2 O2ER ≤ 27% FloTrac/Vigileo Fluid inotropes vasopressors
Lai CW
2015 [31]		 Major abdominal 109 111 High NR SVV < 10% – LiDCOrapid Fluid
Liang M
2017 [32]		 Urologic 30 30 High 60–80 SVV 8%–13% DO2I ≥ 500 mL/min/m2 FloTrac/Vigileo Fluid inotropes
Lopes MR
2007 [33]		 High risk 17 16 High > 18 PPV < 10% – IBPplus Fluid
Luo J
2017 [34]		 Craniotomy 73 72 High > 18 SVV < 15% CI > 2.5 L/min/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Mayer J
2010 [35]		 Major abdominal 30 30 High > 18 SVV < 12% CI > 2.5 L/min/m2 SVI > 35 mL/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Peng K
2014 [36]		 Major orthopedic 40 40 High > 18 SVV < 10%/14% – FloTrac/Vigileo Fluid vasopressors
Pösö T
2014 [37]		 Abdominal 30 20 Moderate NR SVV < 12% CI ≥2.0 L/min/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Ramsingh DS
2013 [38]		 Major abdominal 18 20 High > 18 SVV < 12% – FloTrac/Vigileo Fluid
Salzwedel C
2013 [39]		 Major abdominal 79 81 High NR PPV < 10% CI > 2.5 L/min/m2 ProAQT Fluid inotropes vasopressors
Scheeren TW
2013 [40]		 High risk 26 26 High > 18 SVV < 10% SV rise > 10% FloTrac/Vigileo Fluid
Stens J
2015 [41]		 Abdominal 13 18 Moderate > 18 PPV < 12% CI > 2.5 L/min/m2 Nexfinb Fluid inotropes vasopressors
Sundaram SC
2016 [42]		 Intracranial tumor 30 30 High 20–80 PPV < 13% – Phillips Intellivue MP50 Fluid vasopressors
Weinberg L
2017 [43]		 Major abdominal 26 26 High > 18 SVV < 20% CI > 2.0 L/min/m2 PaO2 > 100 mmHg Hb > 8 g/dL T > 36 °C FloTrac/Vigileo Fluid inotropes vasopressors
Wu J
2017 [44]		 Intracranial tumor 33 30 High NR SVV < 12% CI > 2.5 L/min/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Xu H
2017 [45]		 Thoracic 84 84 Moderate 18–60 SVV 10– 13% CI > 2.5 L/min/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Yu Y
2014 [46]		 Abdominal 15 15 Moderate 20–65 PVI < 13% – Masimo Radical 7b Fluid vasopressors
Zhang J
2013 [47]		 Thoracic 30 30 Moderate 18–60 SVV 9– 11% CI > 2.5 L/min/m2 FloTrac/Vigileo Fluid inotropes
Zheng H
2013 [48]		 Major abdominal 30 30 High 60–80 SVV < 12% CI > 2.5 L/min/m2 SVI > 35 mL/m2 FloTrac/Vigileo Fluid inotropes vasopressors
Zheng LS
2016 [49]		 Major abdominal 39 37 High 65–90 SVV < 12% CI > 2.5 L/min/m2 FloTrac/Vigileo Fluid vasopressors

CIx cardiac index, CO cardiac output, DO2 oxygen delivery, GDFT goal-directed fluid therapy, GDFTdyn goal-directed fluid therapy based on dynamic variables, Hb hemoglobin, Hct Red blood cell specific volume, NR not reported, O2ER O2 extraction rate, PaO2 partial pressure of oxygen, PPV pulse pressure variation, PVI pleth variability index; ScVO2 systemic central venous oxygen saturation, SPV systolic pressure variation, SV stroke volume, SVI stroke volume index, SVR systemic vascular resistance, SVRI systemic vascular resistance index, SVV stroke volume variation, T temperature

aAlgorithms for GDFTdyn in these studies were performed intraoperatively and shortly after surgery, while others were performed only intraoperatively

bMonitoring devices in these studies were non-invasive, while others were minimally invasive